参附注射液对COVID-19危重症患者器官功能障碍复合结局影响的随机对照试验方案摘要
本研究为多中心、随机、对照、开放标签、1:1平行组临床试验,计划纳入300例18-75岁确诊或疑似重型/危重型COVID-19患者,评估参附注射液对器官功能障碍复合结局的保护作用。主要终点为入组后14天内SOFA评分较基线增加≥2分(提示脓毒症且至少一个器官受累)。
要点
- 参附注射液组每日两次100ml,对照组等量生理盐水,连续7天,均接受常规支持治疗。
- 主要终点为14天内新发或加重的器官功能障碍(SOFA评分增加≥2分)。
- 计划纳入300例患者,来自中国5个城市11个ICU,随机1:1分组。
核心结论
- 该研究旨在确定参附注射液对COVID-19危重症患者器官功能障碍发展的保护作用,目前仅为研究方案摘要,尚无结果结论。
研究设计与样本
- 多中心、随机、对照、开放标签、两臂1:1平行组临床试验,计划纳入300例18-75岁确诊或疑似重型/危重型COVID-19患者,来自中国5个城市11个ICU。
关键数值与推荐
- 主要终点为入组后14天内SOFA评分较基线增加≥2分,提示脓毒症且至少一个器官受累。
- 次要终点包括总SOFA评分、肺炎严重指数评分、血管活性药物剂量、28天内无通气天数、ICU住院时长、总住院费用、28天死亡率及参附注射液相关不良事件发生率。
局限性
- 开放标签设计,仅患者和统计人员设盲,医护人员未设盲。
- 研究方案版本2.0(2020年2月15日),计划招募截止2020年8月31日,尚未报告结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to determine the protection provided by Shenfu injection (a traditional Chinese medicine) against development of organ dysfunction in critically ill patients with coronavirus disease 2019 (COVID-19). TRIAL DESIGN: This study is a multicenter, randomized, controlled, open-label, two-arm ratio 1:1, parallel group clinical trial. PARTICIPANTS: The patients, who are aged from 18 to 75 years old, with a confirmed or suspected diagnosis of severe or critical COVID-19, will be consecutively recruited in the study, according to the guideline on diagnosis and treatment of COVID-19 (the 7th version) issued by National Health Commission of the People's Republic of China. Exclusion criteria include pregnant and breastfeeding women, atopy or allergies to Shenfu Injection (SFI), severe underlying disease (malignant tumor with multiple metastases, uncontrolled hemopathy, cachexia, severe malnutrition, HIV), active bleeding, obstructive pneumonia caused by lung tumor, severe pulmonary interstitial fibrosis, alveolar proteinosis and allergic alveolitis, continuous use of immunosuppressive drugs in last 6 months, organ transplantation, expected death within 48 hours, the patients considered unsuitable for this study by researchers. The study is conducted in 11 ICUs of designated hospitals for COVID-19, located in 5 cities of China. INTERVENTION AND COMPARATOR: The enrolled patients will randomly receive 100 ml SFI (study group) or identical volume of saline (control group) twice a day for seven consecutive days. Patients in the both groups will be given usual care and the necessary supportive therapies as recommended by the latest edition of the management guidelines for COVID-19 (the 7th version so far). MAIN OUTCOMES: The primary endpoint is a composite of newly developed or exacerbated organ dysfunction. This is defined as an increase in the sequential organ failure assessment (SOFA) score of two or more, indicating sepsis and involvement of at least one organ. The SOFA score will be measured for the 14 days after enrolment from the baseline (the score at randomization). The secondary endpoints are shown below: • SOFA score in total • Pneumonia severity index score • Dosage of vasoactive drugs • Ventilation free days within 28 days • Length of stay in intensive care unit • Total hospital costs to treat the patient • 28-day mortality • The incidence of adverse drug events related to SFI RANDOMISATION: The block randomization codes were generated by SAS V.9.1 for allocation of participants in this study. The ratio of random distribution is 1:1. The sealed envelope method is used for allocation concealment. BLINDING (MASKING): The patients and statistical personnel analyzing study data are both blinded. The blinding of group assignment is not adopted for the medical staff. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): This study is expected to recruit 300 patients with COVID-19, (150 in each group). TRIAL STATUS: Protocol version 2.0, February 15, 2020. Patient recruitment started on February 25, and will end on August 31, 2020. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR2000030043. Registered February 21, 2020, http://www.chictr.org.cn/showprojen.aspx?proj=49866 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
引用
- Wang ZY, Fu SZ, Xu L, et al. Impact of Shenfu injection on a composite of organ dysfunction development in critically ill patients with coronavirus disease 2019 (COVID-19): A structured summary of a study protocol for a randomized controlled trial. Trials. 2020. PMID: 32831151. doi:10.1186/s13063-020-04677-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。